



YOUR VISION IS OUR VISION™

## Oxurion Provides Further Details Concerning the Second Amendment to Negma Funding Program

January 27, 2023

### Oxurion Provides Further Details Concerning the Second Amendment to Negma Funding Program

**Leuven, BELGIUM, Boston, MA, US – January 27, 2023 8:00 am CET** – Oxurion NV (Euronext Brussels: OXUR) a biopharmaceutical company developing next generation standard of care ophthalmic therapies, with clinical stage assets in vascular retinal disorders, has entered into an amendment of its mandatory convertible bonds issuance and subscription agreement with the Negma Group on January 25, 2023 (“funding program”).

The amendment provides Oxurion access to four million euros in three tranches with a reduced cool down period of fifteen trading days (instead of twenty-two trading days), provided the terms and conditions of the agreement and the bonds are met. Similar to Part B of the funding program, there is no liquidity requirement and the conversion price of the shares is eighty percent of the lowest closing VWAP over the fifteen consecutive trading days in advance of the conversion notice.

### About Oxurion

Oxurion (Euronext Brussels: OXUR) is a biopharmaceutical company developing next generation standard of care ophthalmic therapies, which are designed to improve and better preserve vision in patients with retinal disorders including diabetic macular edema (DME), the leading cause of vision loss in working-age people, as well as other conditions. Oxurion intends to play an important role in the treatment of retinal disorders, including the successful development of THR-149, its novel therapeutic for the treatment of DME. THR-149 is a potent plasma kallikrein inhibitor being developed as a potential new standard of care for the up to fifty percent of DME patients showing suboptimal response to anti-VEGF therapy. Oxurion is headquartered in Leuven, Belgium, with corporate operations in Boston, MA. More information is available at [www.oxurion.com](http://www.oxurion.com).

### Important information about forward-looking statements

Certain statements in this press release may be considered “forward-looking”. Such forward-looking statements are based on current expectations, and, accordingly, entail and are influenced by various risks and uncertainties. The Company therefore cannot provide any assurance that such forward looking statements will materialize and does not assume any obligation to update or revise any forward looking statement, whether as a result of new information, future events, or any other reason. Additional information concerning risks and uncertainties affecting the business and other factors that could cause actual results to differ materially from any forward-looking statement is contained in the Company’s Annual Report. This press release does not constitute an offer or invitation for the sale or purchase of securities or assets of Oxurion in any jurisdiction. No securities of Oxurion may be offered or sold within the United States without registration under the U.S. Securities Act of 1933, as amended, or in compliance with an exemption therefrom, and in accordance with any applicable U.S. state securities laws.

### For further information please contact:

<p>Oxurion NV Tom Graney Chief Executive Officer Tel: +32 16 75 13 10 <a href="mailto:tom.graney@oxurion.com">tom.graney@oxurion.com</a></p> <p>Michaël Dillen Chief Business Officer Tel: +32 16 75 13 10 <a href="mailto:michael.dillen@oxurion.com">michael.dillen@oxurion.com</a></p>	<p>US <a href="http://Conway Communications">Conway Communications</a> Mary T. Conway <a href="mailto:mtconway@conwaycommsir.com">mtconway@conwaycommsir.com</a></p> <p>ICR Westwicke Christopher Brinzey Tel: +1 617 835 9304 <a href="mailto:chris.brinzey@westwicke.com">chris.brinzey@westwicke.com</a></p>
---	---

### Attachment

- [Oxurion Clarification Second Amendment with Negma.FINAL](#)